Inventiva S.A.

NASDAQ:IVA

Biotechnology

Healthcare
$3.39 +0.42%

+$0.02 today

Market cap
$176.22M
Beta
0.88
P/E (TTM)
-5.5
EPS (TTM)
-$0.56
52W Low $2.85High $7.98

Volume 3.54M

Average 0.45M

IVA Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Inventiva S.A.NASDAQ: IVA

Stock-Based Compensation · Q4 FY2025 · quarter ended Dec 2025

Stock-based compensation outflow shrinks to €0

Q4 FY2025 stock-based compensation was €0, compared with €3.58M a year earlier. Over 3 fiscal years it compounded at +129.4% a year.

Context

  • Stock-based compensation amounted to 597.1% of revenue in FY2025, up 558.2 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
€0— QoQ
Last fiscal yearDec 2025
€26.77M+647.7% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+647.7%——
3-year CAGR+129.4%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

EUR · from the cash flow

Latest · FY2025
26.77M EUR
Year-over-year change
+647.7%
4-year CAGR
+89.2%

Stock-Based Compensation vs competitors

How IVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +647.7% is the highest of 10, against a peer median of -32.8%.
  • Stock-based compensation amounts to 597.1% of revenue for IVA, versus a peer median of 99.6%.
IVA Competitors
Stock-Based Compensation for IVA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€26.77M EUR+647.7%+129.4%597.1%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$15.77M USD-32.9%-11.7%22.8%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$13.96M USD+64.9%+21.7%23652.5%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$11.86M USD+7.9%+52.0%36.3%
IVVDInvivyd, Inc.LTM Mar 2026$11.51M USD-33.2%-18.7%20.6%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$11.51M USD-28.1%+4.4%5116.0%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$11.16M USD-32.8%+2.7%99.6%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$10.44M USD+36.3%-2.0%587.9%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$6.04M USD-48.6%-13.0%—
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$1.44M USD-63.8%——
Peer median (excluding IVA) —-32.8%+0.3%99.6%

Competitors are the stored peer set for IVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(49.64M)(54.27M)(110.43M)(184.21M)(340.16M)
Depreciation & Amortization(1.29M)1.7M2.6M5.2M3.22M
Deferred Income Tax(3.27M)(5.26M)(4.74M)(4.8M)(2.3M)
Stock-Based Compensation2.09M2.22M3.97M3.58M26.77M
Change in Working Capital979K5.71M17.31M1.68M6.42M
Accounts Receivables(5.32M)3.84M(5.84M)2.81M816.45K
Inventory(72K)19K(44K)417K0
Accounts Payables7.6M3.54M20M02.46M
Other Working Capital(1.23M)(1.69M)3.19M(1.54M)3.15M
Other Non-Cash Items3.5M4.98M9.68M92.63M205.07M
Operating Cash Flow(47.63M)(44.93M)(81.61M)(85.93M)(100.98M)
Capital Expenditures(534K)(561K)(540K)(333K)(237.26K)
Acquisitions (Net)89K41K000
Purchases of Investments(1.35M)(1K)(8.3M)0(127.69M)
Sales of Investments(89K)9.39M978K9.08M0
Other Investing Activities90K1K131K75.72K(1K)
Investing Cash Flow(1.79M)8.87M(7.73M)8.75M(127.93M)
Debt Repayment(28K)28.44M(4.1M)19.92M(5.98M)
Common Stock Issued25.48M8.83M28.08M57.34M237.74M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(17.73K)(772.47K)5.1M68.33M236.98K
Financing Cash Flow25.45M37.27M29.08M145.59M232M
Effect of Forex Changes4.84M(1.03M)445K1.24M11.08M
Net Change in Cash(19.13M)183K(59.82M)69.65M14.17M
Free Cash Flow(48.16M)(45.49M)(82.15M)(86.26M)(101.22M)

Inventiva S.A.

NASDAQ:IVA

Intrinsic Alpha fair value

Locked

Current Price

$3.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.